Log in

NASDAQ:CYANCyanotech Stock Price, Forecast & News

$2.10
0.00 (0.00 %)
(As of 05/25/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.03
Now: $2.10
$2.13
50-Day Range
$2.03
MA: $2.21
$2.36
52-Week Range
$1.82
Now: $2.10
$3.35
Volume2,764 shs
Average Volume4,114 shs
Market Capitalization$12.45 million
P/E RatioN/A
Dividend YieldN/A
Beta0.61
Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. The company's products include Hawaiian BioAstin natural astaxanthin, a dietary antioxidant, which is used as a human nutraceutical and functional food ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye and joint health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. Cyanotech Corporation sells its products as packaged consumer products through distributors, retailers, and online channels, as well as directly to consumers; and in bulk quantities to manufacturers, formulators, and distributors. The company was founded in 1983 and is headquartered in Kailua-Kona, Hawaii.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.61 out of 5 stars


Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYAN
CUSIPN/A
Phone808-326-1353

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30.20 million
Book Value$2.55 per share

Profitability

Net Income$-3,600,000.00

Miscellaneous

Employees118
Market Cap$12.45 million
Next Earnings Date7/6/2020 (Estimated)
OptionableNot Optionable

Receive CYAN News and Ratings via Email

Sign-up to receive the latest news and ratings for CYAN and its competitors with MarketBeat's FREE daily newsletter.

Cyanotech (NASDAQ:CYAN) Frequently Asked Questions

How has Cyanotech's stock been impacted by COVID-19 (Coronavirus)?

Cyanotech's stock was trading at $1.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CYAN shares have increased by 5.5% and is now trading at $2.10. View which stocks have been most impacted by Coronavirus.

When is Cyanotech's next earnings date?

Cyanotech is scheduled to release its next quarterly earnings announcement on Monday, July 6th 2020. View our earnings forecast for Cyanotech.

How were Cyanotech's earnings last quarter?

Cyanotech Corp (NASDAQ:CYAN) released its quarterly earnings results on Tuesday, February, 11th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter. The biotechnology company had revenue of $7.50 million for the quarter. Cyanotech had a negative net margin of 4.12% and a negative return on equity of 7.93%. View Cyanotech's earnings history.

Has Cyanotech been receiving favorable news coverage?

Media stories about CYAN stock have trended very positive this week, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cyanotech earned a news sentiment score of 4.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news aboutCyanotech.

Are investors shorting Cyanotech?

Cyanotech saw a increase in short interest in May. As of May 15th, there was short interest totaling 8,000 shares, an increase of 233.3% from the April 30th total of 2,400 shares. Based on an average daily trading volume, of 13,500 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.2% of the company's stock are short sold. View Cyanotech's Current Options Chain.

Who are some of Cyanotech's key competitors?

What other stocks do shareholders of Cyanotech own?

Who are Cyanotech's key executives?

Cyanotech's management team includes the following people:
  • Mr. Mawae R. Morton, Chief Exec. Officer (Age 52)
  • Dr. Gerald R. Cysewski Ph.D., Co-Founder, Pres & Vice Chairman (Age 70)
  • Mr. Brian Brett Orlopp, VP of Fin. & CFO and Sec.
  • Mr. Glenn D. Jensen, VP of Manufacturing & Infrastructure (Age 61)

What is Cyanotech's stock symbol?

Cyanotech trades on the NASDAQ under the ticker symbol "CYAN."

Who are Cyanotech's major shareholders?

Cyanotech's stock is owned by a number of retail and institutional investors. Top institutional investors include Morgan Stanley (0.25%). View institutional ownership trends for Cyanotech.

Which institutional investors are selling Cyanotech stock?

CYAN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley. View insider buying and selling activity for Cyanotech.

How do I buy shares of Cyanotech?

Shares of CYAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cyanotech's stock price today?

One share of CYAN stock can currently be purchased for approximately $2.10.

How big of a company is Cyanotech?

Cyanotech has a market capitalization of $12.45 million and generates $30.20 million in revenue each year. Cyanotech employs 118 workers across the globe.

What is Cyanotech's official website?

The official website for Cyanotech is www.cyanotech.com.

How can I contact Cyanotech?

Cyanotech's mailing address is 73-4460 QUEEN KAAHUMANU HWY SUITE 102, KAILUA KONA HI, 96740. The biotechnology company can be reached via phone at 808-326-1353 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.